Open AccessEfficacy of risedronate in a post-menopausal woman affected by osteoporosis and inflammatory bowel disease
Author(s) -
Stefano Palomba,
Morena Rocca,
Angela Falbo
Publication year - 2010
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i2.532
Subject(s) - medicine , osteoporosis , asymptomatic , inflammatory bowel disease , bone mineral , bisphosphonate , disease , bone remodeling , quality of life (healthcare) , bone disease , osteopenia , nursing
Post-menopausal osteoporosis is a skeletal disease that can be asymptomatic and is sometimes underdiagnosed and undertreated. Post-menopausal osteoporosis can be associated with fractures and consequent impaired quality of life and increase of health care costs. Bisphosphonates are a therapeutic choice, because they proved to be effective in preventing bone loss. The current case report shows the efficacy of six-month risedronate administration in a post-menopausal woman affected by osteoporosis and inflammatory bowel disease in reducing biochemical bone turnover markers and increasing bone mineral density